Want to see TRVI full AI Analyst Report?
Trevi Therapeutics (TRVI) Income Statement
Trevi Therapeutics Income Statement
Last quarter (Q2 2026), Trevi Therapeutics's total revenue was $0.00. In Q2, Trevi Therapeutics's net income was $-17.80M. See Trevi Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 0.00 | $ -147.00K | $ 0.00 | $ 0.00 | $ -50.00K | |
| $ 49.33M | $ 51.52M | $ 33.92M | $ 29.91M | $ 32.48M | |
| Depreciation and Amortization | $ 144.00K | $ 147.00K | $ 123.00K | $ 43.00K | $ 50.00K |
| $ -42.68M | $ -47.79M | $ -28.58M | $ -27.98M | $ -32.71M | |
| $ -49.33M | $ -51.52M | $ -33.92M | $ -29.91M | $ -32.48M | |
| $ 6.50M | $ 3.58M | $ 4.83M | $ 719.00K | $ -1.49M | |
| $ -42.82M | $ -47.94M | $ -29.10M | $ -29.19M | $ -33.96M | |
| $ -42.76M | $ -47.91M | $ -29.07M | $ -29.15M | $ -33.94M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.29 | $ -0.47 | $ -0.29 | $ -0.45 | $ -1.49 |
| Diluted EPS | $ -0.29 | $ -0.47 | $ -0.29 | $ -0.45 | $ -1.49 |
| Weighted Average Shares Outstanding | 145.10M | 101.04M | 99.03M | 64.54M | 22.84M |
| Weighted Average Shares Outstanding (Diluted) | 145.10M | 101.04M | 99.03M | 64.54M | 22.84M |
Currency in USD
